Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action

Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action

Tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor, is approved worldwide for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH-LUTS). The purpose of this narrative review is to summarize the clinical data on tadalafil 5 mg once-daily, primarily focusin...

Full description

Bibliographic Details
Main Authors: Osamu Yokoyama, Yasuhiko Igawa, Masayuki Takeda, Takafumi Yamaguchi, Masahiro Murakami, Lars Viktrup
Format: Article
Language:English
Published: SAGE Publishing 2015-10-01
Series:Therapeutic Advances in Urology
Online Access:https://doi.org/10.1177/1756287215589238

Similar Items

Similar Items